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Mean (SEM) Naive Sham Injected Acute Arthritis MOR Rx Acute Arthritis MOR Alone CAP Pre-treatment CAP Alone Day 6
EPS 0.87 (0.41) 1.67 (0.88) 6.57 (1.01) 0.67 (0.42) 1.88 (0.85) 3.2 (0.58) 1.67 (1.67)
DWB (L/R) % Weight 102.6 (2.47) 96.3 (8.56) 83.7 (5.26) 98.4 (6.35) 96.2 (1.95) 106.4 (7.96) 104.1 (10.59)
DWB (L/R)% Time on Limb 100.6 (0.97) 100.0 (1.60) 94.7 (2.16) 99.9 (0.59) 99.2 (0.80) 99.07(1.98) 101.1 (1.91)
Results (Values in bold and italics p<.05)
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S270(0.15mg/knee). Some mice were injected IA with CAP (0.305 mmol)
7 days before induction of arthritis. DWBwasmeasured with a Dynamic
Weight Bearing apparatus (Bioseb, Vitrolles, France). Evoked pain scores
were derived by tallying ﬁghts + vocalizations/1 minwith repeated ﬁrm
palpation of the knee. Substance P signal intensity from ipsilateral and
contralateral DRGs in the lumbar region were compared by immuno-
histochemistry. Development of inﬂammatory arthritis was conﬁrmed
by histology.
Results: Arthritis pain was clearly and reproducibly indicated by
increased EPS in arthritic mice. DWB was signiﬁcantly reduced by
acute arthritis in the affected limb measured by both % weight bearing
and time on the affected limb. IA MOR improved EPS and DWB by all
measures. Pretreatment with capsaicin abolished the increased EPS
from carrageenan arthritis and normalized DWB by all measures. IA
CAP injection alone had no effect on DWB or EPS by day 6. Substance
P signal intensity appeared to be higher in the ipsilateral DRG
compared to the contralateral in arthritic animals. Articular inﬂam-
mation in CAR induced arthritic mice was not prevented by CAP.-
Conclusions: Pain can be quantitated in murine arthritis models using
measures of DWB and EPS. EPS increased and DWB of the affected limb
decreased signiﬁcantly with acute inﬂammatory arthritis. Analgesia
produced by IA MOR was detected by both DWB and EPS in arthritic
mice. Arthritic animals pretreated with capsaicin did not develop pain
as measured by EPS or DWB though there was histologic evidence for
acute inﬂammation. DWB appears to have signiﬁcant utility for
measuring arthritis pain in animal models. It is sensitive to change, has
good reproducibility between mice and is highly correlated with other
measure of arthritis pain in mice.524
ASSESSING THE EFFICACY OF A VISCOSUPPLEMENT COMBINING
HYALURONIC ACID AND SORBITOL (SYNOLIS-VA) IN PATIENTS
WITH HIGH GRADES KNEE OSTEOARTHRITIS FOR WHOM
CORTICOTHERAPY IS CONTRAINDICATED
M. Bausani. Ortopedia e Traumatologia, Siena, Italy
Purpose: Synolis-VA is an innovative viscosupplement (VS) combining
a high concentration (20 mg/ml) of a > 2 MDa Sodium Hyaluronate
(NaHa) from non animal origin with a high concentration of Sorbitol
(40mg/ml), an oxygen free radical (OFR) scavenger. The strong ability of
Sorbitol to scavenge and neutralize OFR has already been proven to
delay the degradation of the NaHA chains. We hypothesis that the
antioxidant effect of Sorbitol allows reduction of the oxidative stress
affecting chondrocytes and synoviocytes and would therefore play
a fast and durable pain relief effect in patients with high grades knee OA
and with no access to corticotherapy.
Methods: 11 patients with high Kellgren-Lawrence grades symptomatic
Knee OA and contraindication for corticotherapy were included in a 26
weeks prospective open pilot study. Treatment regimen consisted of 3
IA injections of 2 ml of Synolis-VA on week apart. Pain and function
measures using walking pain (WP) 5 points Likert scale (0 to 4),
WOMAC A pain (0 to 20) and WOMAC stiffness (0 to 8) scores were
obtained at W0, W1, W2 and W13 and W26.
Results: 10 patients out of the 11 included in the study were diagnosed
with KL grade IV.
At W0 mean WP was at 3.5, WOMAC pain was 15.2 and WOMAC stiff-
ness was 5.4. At W2, one week after the 2nd Synolis VA injection, re-
ported scores were at their lowest for WP at 2.2 (-37%), WOMAC pain at
10.6 (-32%) and WOMAC stiffness at 2.5 (-53%), with 11 responders. 26
weeks after treatment initiation, scores were still signiﬁcantly
improved forWP at 2.5 (-29%), WOMAC pain at 11.8 (-22%) andWOMAC
stiffness at 3.1 (-43%) with 10 responders, demonstrating prolonged
signiﬁcant activity up to 26 weeks.
Conclusions: This study demonstrates a quick and strong pain relief
occurring immediately after the ﬁrst injection of Synolis-VA. Treat-
ment's beneﬁts were still strongly noticeable at the end of follow-up(W26) despite most of patients diagnosed with Kellgren-Lawrence
grade IV (10 out of 11 patients) and despite the absence of cortico-
therapy.
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PARENTERAL ILOPROST IN THE SYMPTOMATIC TREATMENT OF HIP
OSTEOARTHRITIS
A.-T.D. Magbitang, A. Rubio, M. Tee. Univ. of the Philippines, Philippine
Gen. Hosp., Manila, Philippines
Background: Iloprost is a prostacyclin analogue that has been used in
the treatment of symptomatic bone marrow edema of different
aetiology.
Objective: To present a case of bilateral hip osteoarthritis treated with
intravenous iloprost.
Case: A 32-year old Filipino female presented with pain in the lower
back and bilateral hip of two years duration, precipitated by weight-
bearing activities such as prolonged standing and walking long-
distances, and temporarily relieved by rest. She had no known
co-morbid conditions, denied intake of any herbal or over-the-counter
medications, but had a history of practicing mixed-martial arts for eight
years. Complete blood count, blood chemistries and inﬂammatory
markers were all normal. Radiographs of the hips showed sclerosis on
the superior portion of the left acetabulum consistent with osteode-
generative changes. Magnetic resonance imaging of the hips revealed
subtle heterogenous marrow signals within both acetabulum and
femoral heads with minimal effusion. Bone marrow edema, probably of
osteoarthritic etiology was diagnosed. Beginning avascular necrosis was
also considered.
The patient was given Iloprost 20 ug daily intravenous infusions for six
doses. No untoward event was noted. Hip pain decreased by 50% after
the second dose (from VAS 7/10 to VAS 3/10), and completely resolved
after the ﬁfth dose. The patient was subsequently advised off-loading
for 3 to 4 weeks and was prescribed physical therapy for gait training.
Conclusion: Iloprost is a prostacyclin analogue that may be used in the
symptomatic treatment of bone marrow edema of different causes,
including osteoarthritis.
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QUANTITATIVE PROTEOMIC ANALYSIS OF HUMAN BONE MARROW
MESENCHYMAL STEM CELLS SECRETOME DURING
CHONDROGENESIS
B. Rocha y, V. Calamia y, V. Casas z, L. Lourido y, C. Fernández y,
J. Mateos y, P. Fernández-Puente y, M. Carrascal z, F.J. Blanco y, C. Ruiz-
Romero y. yOsteoarticular and Aging Res. Lab., Proteomics Unit-
Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain;
z Laboratorio de Proteómica CSCIC/UAB, Barcelona, Spain
Purpose: A major limited factor for the application of human bone
marrow mesenchymal stem cells (hBMSCs) in cartilage tissue engi-
neering is our understanding of the process by which cartilage is
developed, termed chondrogenesis. This multi-step process is regulated
by a variety of growth factors, including bone morphogenic proteins
and transforming growth factor b (TGF-b) proteins. In addition, chon-
drogenic differentiation is alsomodulated by extracellular matrix (ECM)
proteins. Considering that the functional role for the majority of these
secreted proteins during chondrogenesis process is not fully estab-
lished, we have applied SILAC (Isotope Labeling by Amino Acids in Cell
Culture) technique to analyze the extracellular protein expression
proﬁle of hBMSCs undergoing chondrogenic differentiation.
Methods: hBMSCs isolated from 3 osteoarthritic (OA) patients were
grown in SILAC DMEM with different isotope variants of lysine and
arginine between 4-6 weeks. The fully labelled cell populations were
then subjected to chondrogenesis under a home-made medium con-
taining 10 ng/ml TGF-b3 and other factors for 14 days. 24 h before
collecting the secretome, the micromasses were carefully washed and
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inducers. Expression of cartilage speciﬁc genes such as type I and II
collagen and proteoglycans were used to verify the chondrogenicity of
hBMSCs. Proteins in the CM harvested on day 2 and 14 of differentiation
were precipitated and combined at a 1:1 ratio. Each mixture was then
separated by 1D-SDS-PAGE and subjected to in-gel trypsin digestion
using an automatic digester. The resulting peptide mixtures were
analyzed by nanoscale liquid chromatography coupled on-line to an
LTQ-Orbitrap XLmass spectrometer and quantiﬁed using the MaxQuant
software.
Results: A progressive increase of type II collagen, agreccan and chon-
droitin-6-sulfate during the course of 14 days of differentiation was
detected by immunohistochemical assays, suggesting that hMSCs
maintain their chondrogenic capacity in SILAC medium. Using the
metabolic labeling strategy, we compared the secretomes at two
different time points of chondrogenesis. More than 1000 proteins were
identiﬁed with high conﬁdence parameters. 20% of them were previ-
ously known ECM-related proteins. Among these, 34 exhibited
a signiﬁcant modulation of their levels during the process of chondro-
genesis, including cartilage ECM proteins such as COMP, lumican, pro-
largin, ﬁbromodulin and matrix gla protein (MGP), which could be
involved in the organization and/or stabilization of cartilage matrix. All
these proteins were increased at day 14 of chondrogenesis. Finally,
pentraxin-related protein (PTX3), which plays a role in the regulation of
inﬂammatory response, resulted decreased at day 14.
Conclusions: This study was focused on characterizing the speciﬁc
modulations in the secretome of hBMSCs undergoing chondrogenesis
using the SILAC method. The identiﬁcation and quantiﬁcation of these
secreted proteins provide information about the changes in the ECM
synthesis during the differentiation process. Moreover, these ﬁndings
enhance our knowledge of extracellular regulation of this process and
allow the identiﬁcation of extracellular markers of chondrogenesis,
which might have potential value in cartilage regeneration strategies.
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ANTI-ANGIOGENIC ACTION OF CHONDROITIN SULFATE: A NOVEL
TARGET FOR OSTEOARTHRITIS THERAPY
V. Calamia y, J. Mateos y, P. Fernandez-Puente y, L. Lourido y, B. Rocha y,
C. Fernandez-Costa y, E. Montell z, J. Vergés z, C. Ruiz-Romero y, F.J.
Blanco y. yOsteoarticular and Aging Res. Lab., Proteomics Unit-Associated
Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain; z Pre-clinical
R&D Area, Pharma Sci. Div., Bioibérica, Barcelona, Spain
Purpose: Recent works by our group provide evidences of the useful-
ness of proteomics techniques for anti- osteoarthritis (OA) drug
screening. The aim of this study is to identify protein markers for
monitoring chondroitin sulfate (CS) treatment by OA chondrocytes
secretome analysis using the iTRAQ technique.
Methods:Human articular chondrocytes (HACs) released from three OA
cartilages were cultured in DMEM supplemented with antibiotics and
10% FBS. At conﬂuence, OA chondrocytes were treated with 200 mg/mL
of CS (100% purity, bovine origin). 48 hours later, conditioned media
were collected and their proteins were concentrated and quantiﬁed.
Trypsin digestion and labeling with isobaric tags using iTRAQ reagents
were performed. Then, peptides from the two conditions (untreated,Table 1
Left panel: proteins increased by CS. Right panel: proteins decreased by CS.
Protein name Ratio p Value
Aggrecan core protein 1,57 0
Annexin A1 2,08 0,0144
Annexin A2 1,31 0,0365
Annexin A5 1,50 0,0091
Coiled-coil domain-containing
protein 80
1,77 0,0001
Connective tissue growth factor 1,84 0,0009
Extracellular sulfatase Sulf-1 2,11 0,0402
Glia-derived nexin 1,73 0
Hyaluronan and proteoglycan
link protein 1
1,74 0,0028
Target of Nesh-SH3 1,61 0,0019
Tenascin 1,71 0
Thrombospondin-1 1,90 0
Vascular cell adhesion protein 1 1,44 0,0039and CS-treated) were mixed, separated by reversed-phase liquid chro-
matography (LC) and analyzed by nanoscale reversed-phase LC coupled
to mass spectrometry (nLC-MALDI-MS/MS). The identiﬁcation and
quantiﬁcation of proteins (by calculating the different iTRAQ tag
intensities for each peptide) was carried out with Protein Pilot 4.0
software. Real-time, western blot, and immunohistochemistry analyses
were performed to validate our results.
Results: Database search (UniprotKB/Swissprot) allowed the identiﬁ-
cation of 260 different proteins secreted by OA chondrocytes. Among
them, we found 23 secreted proteins presenting statistically signiﬁcant
differences in abundance (p0.05) between treated and untreated
samples: 13 were increased by CS treatment and 10were decreased (see
Table 1). We considered only those proteins with a probability score
higher than 95%, a ratio 1.3 or -1.3, and an error factor <2. We have
successfully quantiﬁed the increase of extracellular matrix components
like aggrecan and other proteoglycans, and the decrease of degradative
enzymes such as cathepsins, caused by the administration of CS.
Annexins were increased by the drug while a glycolytic enzyme was
decreased. Finally we found altered several proteins involved in cell
adhesion and angiogenesis; among them we observed a strong CS-
dependent increase of an angiogenesis inhibitor, thrombospondin-1
(TSP1). Owing to the pivotal role of angiogenesis in OA physiopathology,
we decided to verify TSP1 gene expression level in CS-treated chon-
drocytes by real time-PCR analysis. TSP1 protein level was also veriﬁed
in chondrocyte conditioned media (secretome) and cellular extracts
(proteome) by western blot analyses, and in cartilage explants by
immunohistochemistry. The results obtained in the validation experi-
ments conﬁrmed the proteomics data.
Conclusions: We have found that isobaric tags using iTRAQ reagents is
one of the most promising strategies for accurate comparative proteo-
mics using HACs. We have generated a quantitative proﬁle of chon-
drocyte extracellular protein changes driven by CS in OA.
Demonstration of the anti-angiogenic action of CS might provide
a novel therapeutic approach for OA targeting. This study, however, has
been limited to an in vitro system. In the next futurewe hope to ﬁnd the
altered secreted proteins circulating in serum of OA patients treated
with CS.
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QUANTITATIVE PROTEOMICS OF DIFFERENT ZONES IN HUMAN
ARTICULAR CARTILAGE REVEALS EARLY CHANGES OF PROTEIN
DISTRIBUTION IN PRECLINICAL KNEE OSTEOARTHRITIS
A. Khabut y, C. Müller z, A. Aspberg x, J. Dudhia k, D. Heinegård y,
P. Önnerfjord y. yClinical Sci., Lund, Sweden; zDept. of Biology,
Copenhagen, Denmark; xDept. of Biology, Copenhagen, Dominica; kVet.
Clinical Sci., London, United Kingdom
Purpose: The progress in proteomics technology development during
the last decade has contributed novel tools for detailed studies of the
composition of tissue extracellular matrix at the protein level including
cartilage and bone. We have used quantitative proteomics for a detailed
study of different zones in articular cartilage to increase our knowledge
of structure in relation to biology and function. In this work we studied
changes in protein abundance in very early osteoarthritic articular knee
cartilage samples in comparison to normal tissue.Protein name Ratio pValue
Alpha-actinin-4 -1,36 0,0338
Calreticulin -2,03 0,0144
Cathepsin D -1,34 0,0462
Cathepsin L1 -1,44 0,0251
Heat shock protein HSP 90-beta -1,77 0,0415
Moesin -1,50 0,038
Protein S100-A6 -1,98 0,0153
Pyruvate kinase isozymes M1/M2 -1,43 0,002
Retinol-binding protein 4 -1,44 0,026
Vimentin -1,42 0,0016
